Skip to content
StackItSmart
DPreclinical / mechanistic only
No human data

GHK-Cu

Copper Peptide

GHK-Cu (glycyl-L-histidyl-L-lysine copper(II), "copper peptide") is a naturally occurring human tripeptide-copper complex found in plasma, saliva and urine whose levels decline with age (roughly 200 ng/mL at age 20 to ~80 ng/mL at 60). It is used cosmetically and in "regenerative"/anti-aging contexts for skin remodeling, wound healing, collagen/glycosaminoglycan stimulation and hair. The evidence base is almost entirely preclinical (cell culture and animal wound models) plus small, largely industry-associated topical cosmetic studies. There are no human randomized trials, no human pharmacokinetic data, and no human safety data for injected or systemic use. GHK-Cu is a copper-delivery molecule: unregulated injectable "research" peptide products carry real risk of copper overload/toxicity, plus the generic injection hazards of non-sterile, non-pharmaceutical material (infection, abscess, contamination, dosing errors). It has no anabolic or hormonal action, so it does not build muscle or alter testosterone, but it is frequently sold in that gray market. Because it is unstudied systemically in humans, most claimed benefits beyond topical skin appearance are unproven, and any injectable use is experimental and should be avoided outside a clinician's supervision.

Clinical readoutPeptide · healing-peptide
Hepatic strainNone
CardiovascularNone
HPTA suppressionNone
Half-life
No human pharmaco…
Route
Studied primarily as a…
Evidence
D
Active
Not characterized in hu…
1·t½2·t½3·t½4·t½5·t½
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ No human pharmacokinetic data for administered GHK-Cu. Endogenous free GHK/GHK-Cu is a small peptide expected to be rapidly cleared; small peptides are generally degraded by plasma and tissue peptidases within minutes, but a specific measured half-life for exogenous dosing is not established in humans.
Pharmacology

Mechanism of action

GHK is a copper(II)-chelating tripeptide (Gly-His-Lys) with a copper affinity similar to the copper-transport site on albumin; it forms the GHK-Cu complex and can shuttle copper into cells. Proposed mechanisms (derived from in vitro and animal work) include: stimulation of dermal fibroblast synthesis of collagen, elastin, and proteoglycans, with biphasic, dose-dependent stimulation of sulfated glycosaminoglycans (dermatan sulfate, heparan sulfate); modulation of matrix metalloproteinases and their inhibitors (tissue remodeling); chemoattraction of macrophages, mast cells and capillary/endothelial cells to injury sites; antioxidant and anti-inflammatory activity (suppression of reactive oxygen species and pro-inflammatory signaling); promotion of keratinocyte and epidermal basal/stem-cell proliferation (increased integrin, p63 expression), an effect partly reproduced by copper-free GHK; and broad modulation of gene expression. Copper itself is a required cofactor for lysyl oxidase and superoxide dismutase, so much of the tissue-repair signal is attributed to targeted copper delivery. These mechanisms are established primarily in cultured human cells and animal models, not in controlled human systemic studies.
Kinetics

Pharmacokinetics

Half-life

No human pharmacokinetic data for administered GHK-Cu. Endogenous free GHK/GHK-Cu is a small peptide expected to be rapidly cleared; small peptides are generally degraded by plasma and tissue peptidases within minutes, but a specific measured half-life for exogenous dosing is not established in humans.

Active duration

Not characterized in humans for any route. Topical/cosmetic effects are assessed over weeks of repeated application, not from single-dose kinetics.

Route

Studied primarily as a topical/cosmetic agent; intact skin poorly absorbs GHK-Cu because it is hydrophilic (essentially no permeation through intact human skin in vitro without microneedle or penetration-enhancement). Injectable/subcutaneous use exists only in the unregulated gray market and has no published human PK. This monograph does not provide guidance to evade any test; the absence of PK data means washout timing is genuinely unknown.

Metabolism & clearance

Presumed proteolytic degradation of the tripeptide and handling of released copper via normal copper homeostasis (albumin/ceruloplasmin transport, biliary excretion). No human ADME/clearance studies for exogenous GHK-Cu.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Topical cosmetic studies report tightening of loose skin and improved elasticity, density and firmness, and reduction of fine lines/wrinkles and photodamage (small, largely industry-associated studies; not high-quality RCTs)
  • In vitro/animal: stimulates dermal fibroblast collagen and glycosaminoglycan (dermatan sulfate, heparan sulfate) synthesis
  • In vitro/animal: accelerates wound healing and tissue remodeling, attracts repair cells, and modulates metalloproteinases
  • In vitro: increases keratinocyte/epidermal basal-cell proliferation and 'stemness' markers (integrin, p63)
  • Antioxidant and anti-inflammatory activity in preclinical models
  • No anabolic, androgenic, fat-loss, or performance-enhancing effect; claims of muscle-building or hormonal benefit are unsupported
  • Proposed neuroprotective/anti-aging and pulmonary/anti-cancer gene-modulation effects remain hypothetical and preclinical only
Safety

Adverse effects by system

Cardiovascular

No human cardiovascular safety data for GHK-Cu by any route. No established cardiotoxic mechanism, but copper overload from parenteral copper-containing products can theoretically stress the cardiovascular system; this is uncharacterized for GHK-Cu specifically.

Hepatic

No human hepatotoxicity data. The peptide has no known intrinsic hepatotoxic mechanism. However, copper is cleared hepatobiliary and excess copper is hepatotoxic; individuals with impaired copper handling (e.g., Wilson's disease) could accumulate copper. No human liver-injury reports for administered GHK-Cu were identified.

Endocrine / HPTA

No hormonal or HPTA activity is described and no human endocrine data exist. GHK-Cu is not androgenic/anabolic and is not expected to suppress the hypothalamic-pituitary-testicular axis, but this has not been formally studied in humans.

Reproductive

No human reproductive or fertility data. Safety in pregnancy and lactation is unknown and it should be avoided in those settings.

Neuropsychiatric

No human psychiatric adverse-effect data. Neuro/cognitive claims are preclinical (aged mice) and hypothetical; no evidence of psychiatric harm or benefit in humans.

Renal

No human renal safety data. No specific nephrotoxic signal identified; copper is only minimally renally excreted, so the kidney is not the primary concern, but this is uncharacterized.

Hematologic

No human hematologic adverse-effect data. Copper is involved in iron metabolism and erythropoiesis; severe copper imbalance can affect blood counts, but no GHK-Cu-specific hematologic toxicity has been reported.

Dermatologic

Most relevant real-world route. Topical use is generally reported as well tolerated in small studies, but copper peptides and topical peptides can cause local irritation, erythema, stinging, and allergic/contact dermatitis in susceptible individuals; copper itself is a recognized contact sensitizer. Injection can cause injection-site reactions, irritation, and infection. Robust human tolerability datasets are lacking.

Recovery

HPTA suppression & recovery

Suppression: None expected / not applicable (no androgenic, anabolic, or hormonal activity); no human data

GHK-Cu is a healing/copper-delivery peptide with no described action on the hypothalamic-pituitary-gonadal axis, so it is not expected to suppress testosterone and does not warrant post-cycle therapy. SERM (single-SERM) protocols are not applicable to this compound and should not be used to 'recover' from it. Because there is no human endocrine study, anyone who experiences symptoms suggesting hormonal disruption while using gray-market products should stop and consult an endocrinologist rather than self-treat.

Bloodwork & vitals

Monitoring

Recommended labs & checks
No validated monitoring protocol exists; if any systemic/injectable use occurs, baseline and periodic serum copper and ceruloplasmin are reasonable given the copper-delivery mechanismLiver function tests (given hepatobiliary copper handling)Complete blood count (copper affects iron/erythropoiesis)Comprehensive metabolic panel / renal function as general parenteral-use safety

Cadence: Not established. For any experimental systemic use, a clinician-directed baseline before use and follow-up if symptoms arise is the conservative approach; topical cosmetic use does not typically require labs but any spreading rash or reaction should prompt evaluation.

Warning signs — seek care
  • Local skin reaction: worsening redness, itching, rash, swelling, blistering, or signs of allergic contact dermatitis
  • Injection-site pain, warmth, pus, or spreading redness (possible infection/abscess)
  • Systemic copper-toxicity-type symptoms: nausea, vomiting, abdominal pain, jaundice, unusual fatigue
  • Any allergic reaction (hives, facial/throat swelling, difficulty breathing) - seek emergency care
  • New or unexplained symptoms while using an unregulated injectable product
Do not use if

Contraindications

  • Wilson's disease or any disorder of copper metabolism/copper overload (GHK-Cu delivers copper)
  • Known copper or peptide/formulation hypersensitivity or copper contact allergy
  • Pregnancy and breastfeeding (no safety data)
  • Active local skin infection at the application/injection site
  • Any injectable use of non-pharmaceutical 'research'/gray-market product, especially non-sterile or unverified purity
  • Caution with concurrent copper supplementation or other copper-containing products (additive copper load)
Combinations

Interaction profile

  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • The evidence for GHK-Cu is overwhelmingly preclinical (cell and animal) plus small topical cosmetic studies; there are no human RCTs, no human pharmacokinetic data, and no human systemic safety data - treat all systemic/injectable use as experimental and unproven
  • Avoid injectable gray-market 'research' peptide products: they carry risks of non-sterility (infection, abscess), unknown purity/dose, and copper overload, none of which are offset by proven benefit
  • Topical use is the only route with human data and is generally better tolerated; patch-test first and stop if irritation, rash, stinging, or allergic contact dermatitis develops
  • Do not combine with other copper-containing products or copper supplements without medical advice, to avoid additive copper load
  • Do not use if you have Wilson's disease or any copper-metabolism disorder, or a known copper/peptide allergy; avoid in pregnancy and breastfeeding
  • This compound is not anabolic or hormonal - it will not build muscle or affect testosterone, and it does not require SERM/PCT; disregard marketing that frames it that way
  • Stop and seek medical care for spreading redness, pus, fever, jaundice, persistent nausea/abdominal pain, or any allergic reaction; involve a clinician (and an endocrinologist for any suspected hormonal symptoms) rather than self-managing
Evidence

Citations (10)

Every clinical claim above is tied to a primary source. Overall evidence grade D — this compound lacks adequate human data; claims rest on preclinical or mechanistic evidence.

  1. 01

    GHK is a naturally occurring human tripeptide (Gly-His-Lys) present in plasma, saliva and urine that forms a copper complex (GHK-Cu) and is proposed to accelerate wound healing and skin repair; stimulates collagen and glycosaminoglycan synthesis and modulates metalloproteinases

    ReviewGHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.PMID 26236730 ↗

  2. 02

    Cosmetic/topical studies on aged skin report tightening of loose skin, improved elasticity, density and firmness, and reduced fine lines, wrinkles, photodamage and hyperpigmentation; GHK-Cu attracts immune and endothelial repair cells and increases synthesis of collagen, elastin and repair growth factors

    ReviewThe human tri-peptide GHK and tissue remodeling.PMID 18644225 ↗

  3. 03

    GHK has a copper(II) affinity similar to the copper-transport site on albumin, forms GHK-Cu, and drives tissue-remodeling processes including chemoattraction of macrophages/mast cells/capillary cells and modulation of metalloproteinases and antiproteases

    ReviewThe human tri-peptide GHK and tissue remodeling.PMID 18644225 ↗

  4. 04

    Plasma GHK levels average ~200 ng/mL at age 20 and decline to ~80 ng/mL by age 60; GHK-Cu has antioxidant and anti-inflammatory properties in in vitro and in vivo models; cognitive/anti-aging effects are preliminary and preclinical (aging mice)

    ReviewThe potential of GHK as an anti-aging peptide.PMID 35083444 ↗

  5. 05

    GHK-Cu possesses antioxidant and anti-inflammatory activity and high affinity for copper ions; proposed neurodegeneration/cognitive applications are hypothetical and based on gene-regulation and preclinical rationale

    ReviewThe human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health.PMID 22666519 ↗

  6. 06

    GHK-Cu produces a biphasic, dose-dependent stimulation of sulfated glycosaminoglycan (dermatan sulfate, heparan sulfate) synthesis in cultured normal human dermal fibroblasts, with maximal effect at low nanomolar concentrations

    PreclinicalPMID 1522753 ↗

  7. 07

    GHK (including copper-free GHK) increases proliferation and stem-cell/basal markers (integrin, p63) of human keratinocytes in monolayer and skin-equivalent models

    PreclinicalStem cell recovering effect of copper-free GHK in skin.PMID 23019153 ↗

  8. 08

    GHK-Cu is hydrophilic and does not meaningfully permeate intact human skin in vitro; delivery required microneedle pretreatment to achieve peptide and copper permeation, underscoring poor absorption through intact skin

    PreclinicalPMID 25690343 ↗

  9. 09

    GHK-Cu accelerates wound healing in a rat dermal model with increased cell proliferation and antioxidant enzyme expression, and its healing activity is linked to copper localization at the wound site (approximately ninefold copper increase)

    PreclinicalPMID 15803494 ↗

  10. 10

    GHK, urocanic acid and Cu(II) co-occur physiologically (e.g., skin, plasma) and GHK binds copper, forming complexes that may mediate its biological effects - supporting GHK-Cu's role as a copper-binding/delivery molecule

    PreclinicalTernary Cu(II) Complex with GHK Peptide and Urocanic Acid as a Potential Physiologically Functional Copper Chelate.PMID 32867146 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice